Association between renal function and the Treatment of Diabetic Macular Edema in Long-Term Cohort Study.
Humans
Macular Edema
/ therapy
Male
Female
Diabetic Retinopathy
/ therapy
Aged
Middle Aged
Retrospective Studies
Intravitreal Injections
Renal Insufficiency, Chronic
/ therapy
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Glomerular Filtration Rate
Visual Acuity
Angiogenesis Inhibitors
/ therapeutic use
Taiwan
/ epidemiology
Treatment Outcome
Follow-Up Studies
Anti-VEGF
Chronic kidney disease
Diabetic macular edema
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 10 2024
30 10 2024
Historique:
received:
01
04
2024
accepted:
23
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
To determine the correlation between the severity of chronic kidney disease (CKD) and treatment of diabetic macular edema (DME). The retrospective 2-year cohort study included eyes with DME confirmed using spectral-domain optical coherence tomography in Taipei Veterans General Hospital, Taiwan, between 2010 and 2020. All the eyes were treated with an intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) during regular follow-up around 2 years. They were categorized into 3 different groups: an estimated glomerular filtration rate ≥ 60 (mL/min per 1.73 m
Identifiants
pubmed: 39478134
doi: 10.1038/s41598-024-77530-3
pii: 10.1038/s41598-024-77530-3
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26098Informations de copyright
© 2024. The Author(s).
Références
Flaxman, S. R. et al. Global causes of blindness and distance vision impairment 1990–2020: A systematic review and meta-analysis. Lancet Glob. Health. 5(12), e1221–e1234 (2017).
doi: 10.1016/S2214-109X(17)30393-5
pubmed: 29032195
Capitão, M. & Soares, R. Angiogenesis and inflammation crosstalk in diabetic retinopathy. J. Cell Biochem. 117(11), 2443–2453 (2016).
doi: 10.1002/jcb.25575
pubmed: 27128219
Yamagishi, S. et al. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr. Pharm. Des. 14(10), 962–968 (2008).
doi: 10.2174/138161208784139729
pubmed: 18473846
Das, A., McGuire, P. G. & Rangasamy, S. Diabetic macular edema: Pathophysiology and novel therapeutic targets. Ophthalmology. 122(7), 1375–1394 (2015).
doi: 10.1016/j.ophtha.2015.03.024
pubmed: 25935789
Hsieh, Y. T. et al. Association of abnormal renal profiles and proliferative diabetic retinopathy and diabetic macular edema in an asian population with type 2 diabetes. JAMA Ophthalmol. 136(1), 68–74 (2018).
doi: 10.1001/jamaophthalmol.2017.5202
pubmed: 29167896
Chen, H. et al. A microalbuminuria threshold to predict the risk for the development of diabetic retinopathy in type 2 diabetes mellitus patients. PLoS One. 7(5), e36718 (2012).
doi: 10.1371/journal.pone.0036718
pubmed: 22590593
pmcid: 3349710
He, B. B. et al. Factors associated with diabetic retinopathy in chinese patients with type 2 diabetes mellitus. Int. J. Endocrinol. 2012, 157940 (2012).
doi: 10.1155/2012/157940
pubmed: 22844279
pmcid: 3400337
Stratton, I. M. et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 44(2), 156–163 (2001).
doi: 10.1007/s001250051594
pubmed: 11270671
Wu, J. et al. The relationship between estimated glomerular filtration rate and diabetic retinopathy. J. Ophthalmol. 2015, 326209 (2015).
pubmed: 25866672
pmcid: 4381716
Rodríguez-Poncelas, A. et al. Chronic kidney disease and diabetic retinopathy in patients with type 2 diabetes. PLoS One. 11(2), e0149448 (2016).
doi: 10.1371/journal.pone.0149448
pubmed: 26886129
Yamamoto, M. et al. Overt proteinuria, moderately reduced eGFR and their combination are predictive of severe diabetic retinopathy or diabetic macular edema in diabetes. Invest. Ophthalmol. Vis. Sci. 60(7), 2685–2689 (2019).
doi: 10.1167/iovs.19-26749
pubmed: 31242290
Romero-Aroca, P., et al., Glomerular filtration rate and/or ratio of urine albumin to creatinine as markers for diabetic retinopathy: a ten-year follow-up study. 2018, 5637130 (2018).
Tsai, M. J. et al. Systemic associations with residual subretinal fluid after Ranibizumab in diabetic macular edema. J. Ophthalmol. 2017, 4834201 (2017).
pubmed: 28819567
Wykoff, C. C. et al. Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials. Ophthalmology. 123(8), 1716–1721 (2016).
doi: 10.1016/j.ophtha.2016.04.004
pubmed: 27208982
Lai, I. P. et al. Renal biomarkers for treatment effect of ranibizumab for diabetic macular edema. J. Diabetes Res. 2020, 7239570 (2020).
doi: 10.1155/2020/7239570
pubmed: 32908935
Tokuyama, T., Ikeda, T. & Sato, K. Effects of haemodialysis on diabetic macular leakage. Br. J. Ophthalmol. 84(12), 1397–1400 (2000).
doi: 10.1136/bjo.84.12.1397
pubmed: 11090481
Tsai, M.-J., Cheng, C.-K. & Wang, Y.-C. Association of body fluid expansion with optical coherence tomography measurements in diabetic retinopathy and diabetic macular edema. Investig. Ophthalmol. Visual Sci. 60(10), 3606–3612 (2019).
doi: 10.1167/iovs.19-27044
Takamura, Y. et al. Functional and anatomical changes in diabetic macular edema after hemodialysis initiation: One-year follow-up multicenter study. Sci. Rep. 10(1), 7788 (2020).
doi: 10.1038/s41598-020-64798-4
pubmed: 32385333
Theodossiadis, P. G. et al. Hemodialysis-induced alterations in macular thickness measured by optical coherence tomography in diabetic patients with end-stage renal disease. Ophthalmologica. 227(2), 90–94 (2012).
doi: 10.1159/000331321
pubmed: 21921588
Ong, S. S., Thomas, A. S. & Fekrat, S. Improvement of recalcitrant diabetic macular edema after peritoneal dialysis. Ophthalmic Surg. Lasers Imaging Retina. 48(10), 834–837 (2017).
doi: 10.3928/23258160-20170928-09
pubmed: 29020428
Wong, W. M. et al. Systemic factors associated with treatment response in diabetic macular edema. J. Ophthalmol. 2020, 1875860–1875860 (2020).
pubmed: 32280516
pmcid: 7125481
Hwang, H. et al. Systemic factors and early treatment response to intravitreal injection for diabetic macular edema: The role of renal function. Retina. 41(6), 1275–1282 (2021).
doi: 10.1097/IAE.0000000000003012
pubmed: 33141788
Go, A. S. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351(13), 1296–1305 (2004).
doi: 10.1056/NEJMoa041031
pubmed: 15385656
Jankowski, J. et al. Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. Circulation. 143(11), 1157–1172 (2021).
doi: 10.1161/CIRCULATIONAHA.120.050686
pubmed: 33720773
pmcid: 7969169
Park, Y. H. et al. The association between chronic kidney disease and diabetic retinopathy: The Korea National Health and Nutrition Examination Survey 2008–2010. PLoS One. 10(4), e0125338 (2015).
doi: 10.1371/journal.pone.0125338
pubmed: 25849364
pmcid: 4388494
Wong, T. Y. et al. Prevalence and risk factors for diabetic retinopathy: The Singapore Malay eye study. Ophthalmology. 115(11), 1869–1875 (2008).
doi: 10.1016/j.ophtha.2008.05.014
pubmed: 18584872
Man, R. E. et al. The association of estimated glomerular filtration rate with diabetic retinopathy and macular edema. Invest. Ophthalmol. Vis. Sci. 56(8), 4810–4816 (2015).
doi: 10.1167/iovs.15-16987
pubmed: 26218909
Klaassen, I., Van Noorden, C. J. & Schlingemann, R. O. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog. Retin. Eye Res. 34, 19–48 (2013).
doi: 10.1016/j.preteyeres.2013.02.001
pubmed: 23416119
Schrijvers, B. F., Flyvbjerg, A. & De Vriese, A. S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 65(6), 2003–2017 (2004).
doi: 10.1111/j.1523-1755.2004.00621.x
pubmed: 15149314
Maharaj, A. S. et al. Vascular endothelial growth factor localization in the adult. Am. J. Pathol. 168(2), 639–648 (2006).
doi: 10.2353/ajpath.2006.050834
pubmed: 16436677
Cha, D. R. et al. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J. Endocrinol. 183(1), 183–194 (2004).
doi: 10.1677/joe.1.05647
pubmed: 15525586
Pawlak, K., Mysliwiec, M. & Pawlak, D. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure. Cytokine. 43(1), 98–101 (2008).
doi: 10.1016/j.cyto.2008.03.011
pubmed: 18455421
Karst, S. G. et al. Atrophy of the central neuroretina in patients treated for diabetic macular edema. Acta ophthalmol. 97(8), e1054–e1061 (2019).
doi: 10.1111/aos.14173
pubmed: 31228332
Jain, A. et al. Status of serum VEGF and ICAM-1 and its association with external limiting membrane and inner segment-outer segment junction disruption in type 2 diabetes mellitus. Mol. Vis. 19, 1760–1768 (2013).
pubmed: 23922493
Nguyen, Q. D. et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 119(4), 789–801 (2012).
doi: 10.1016/j.ophtha.2011.12.039
pubmed: 22330964
Elman, M. J. et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 117(6), 1064-1077.e35 (2010).
doi: 10.1016/j.ophtha.2010.02.031
pubmed: 20427088
Wells, J. A. et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 123(6), 1351–1359 (2016).
doi: 10.1016/j.ophtha.2016.02.022
pubmed: 26935357
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 44(8), 968–83 (1995).
Speeckaert, M. et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?. Nephrol. Dial. Transplant. 29(12), 2167–2177 (2014).
doi: 10.1093/ndt/gfu006
pubmed: 24470517
Tsai, W. C. et al. Risk factors for development and progression of chronic kidney disease: A systematic review and exploratory meta-analysis. Medicine (Baltimore). 95(11), e3013 (2016).
doi: 10.1097/MD.0000000000003013
pubmed: 26986114
Hunsicker, L. G. et al. Predictors of the progression of renal disease in the modification of diet in renal disease study. Kidney Int. 51(6), 1908–1919 (1997).
doi: 10.1038/ki.1997.260
pubmed: 9186882
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39(2 Suppl 1), S1-266 (2002).